Elite Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	140.12	84.04	56.63	34.16	32.26	25.38
Revenue Growth (YoY)	100.18%	48.42%	65.79%	5.87%	27.11%	41.05%
Cost of Revenue	68.57	43.96	30.27	17.56	17.47	13.51
Gross Profit	71.55	40.09	26.36	16.59	14.8	11.87
Selling, General & Admin	11.93	9	7.15	5.12	4.46	3.32
Research & Development	6.14	7.96	6.88	6.2	4.05	5.11
Operating Expenses	19.86	18.88	15.57	12.63	9.72	9.76
Operating Income	51.68	21.2	10.79	3.97	5.07	2.1
Interest Expense	-0.51	-0.77	-0.59	-1.11	-0.19	-0.26
Interest & Investment Income	0.1	0.02	0.02	0.01	0	0
Other Non Operating Income (Expenses)	5.56	-18.9	-11.52	0.42	1.43	1.24
EBT Excluding Unusual Items	56.84	1.55	-1.3	3.28	6.3	3.08
Gain (Loss) on Sale of Assets	-	-	-	1	-	0.05
Asset Writedown	-1.6	-1.6	-	-0.29	-	-
Other Unusual Items	-	-	1.76	-	0.86	1.96
Pretax Income	55.23	-0.05	0.46	3.99	7.16	5.09
Income Tax Expense	11.82	4.26	-19.65	0.42	-1.74	-
Net Income	43.41	-4.31	20.11	3.56	8.9	5.09
Net Income to Common	43.41	-4.31	20.11	3.56	8.9	5.09
Net Income Growth	-	-	464.56%	-59.97%	74.87%	-
Shares Outstanding (Basic)	1,071	1,068	1,015	1,013	1,011	943
Shares Outstanding (Diluted)	1,108	1,068	1,023	1,013	1,011	943
Shares Change (YoY)	4.95%	4.40%	1.02%	0.23%	7.17%	-5.06%
EPS (Basic)	0.04	-0.00	0.02	0.00	0.01	0.01
EPS (Diluted)	0.04	-0.00	0.02	0.00	0.01	0.00
EPS Growth	-	-	537.54%	-57.99%	81.05%	-
Free Cash Flow	17.24	5.83	-4.04	-2.4	6.01	2.86
Free Cash Flow Per Share	0.02	0.01	-0.00	-0.00	0.01	0.00
Gross Margin	51.06%	47.70%	46.55%	48.58%	45.86%	46.76%
Operating Margin	36.89%	25.23%	19.05%	11.62%	15.72%	8.29%
Profit Margin	30.98%	-5.13%	35.51%	10.43%	27.58%	20.05%
Free Cash Flow Margin	12.30%	6.94%	-7.14%	-7.02%	18.63%	11.28%
EBITDA	53.27	22.89	12.16	5.23	6.27	3.4
EBITDA Margin	38.02%	27.24%	21.47%	15.32%	19.42%	13.41%
D&A For EBITDA	1.59	1.69	1.37	1.26	1.19	1.3
EBIT	51.68	21.2	10.79	3.97	5.07	2.1
EBIT Margin	36.89%	25.23%	19.05%	11.62%	15.72%	8.29%
Effective Tax Rate	21.40%	-	-	10.64%	-	-
Revenue as Reported	140.12	84.04	56.63	34.16	32.26	25.38

Source: S&P Global Market Intelligence. Standard template. Financial Sources.